항아밀로이드 항체 시장 보고서(2026년)

Anti-amyloid antibodies are monoclonal antibodies or immunotherapy-based agents developed to specifically target amyloid proteins, particularly amyloid-beta (AB) plaques that build up in the brain and are strongly linked to Alzheimer's disease. These antibodies function by attaching to amyloid deposits, facilitating their removal, decreasing plaque accumulation, and potentially helping to slow neurodegeneration and the progression of cognitive impairment.

The primary product types of anti-amyloid antibodies consist of monoclonal antibodies, polyclonal antibodies, and other product types. Monoclonal antibodies are highly targeted laboratory-developed antibodies created to address amyloid-associated proteins involved in neurological disorders. These products are classified according to target type, including amyloid beta plaques, soluble amyloid beta oligomers, protofibrils, and amyloid precursors, and are distributed through direct sales, online pharmacies, retail pharmacies, and other distribution channels. Their applications encompass Alzheimer's disease, Parkinson's disease, amyloidosis, and other conditions, and they are used by end users such as hospitals, clinics, research institutes, and others.

Tariffs are influencing the anti-amyloid antibodies market by raising the cost of imported biologic raw materials, specialized reagents, and biopharmaceutical manufacturing equipment required for monoclonal antibody production. This is disrupting clinical trial timelines and commercial supply chains, particularly in regions reliant on imports such as Asia-Pacific and parts of Europe. Biotech and pharmaceutical segments focused on monoclonal antibodies and advanced biologics are most affected due to dependence on cross-border research inputs and production infrastructure. However, tariffs are also driving localized biologics manufacturing, strengthening domestic biotech ecosystems, and accelerating investment in regional antibody production capabilities, ultimately improving long-term supply resilience.

The anti-amyloid antibodies market size has grown rapidly in recent years. It will grow from $3.27 billion in 2025 to $3.75 billion in 2026 at a compound annual growth rate (CAGR) of 14.7%. The growth in the historic period can be attributed to increasing global prevalence of Alzheimer's disease, inadequate effectiveness of symptomatic treatments for neurodegeneration, rising research funding for the amyloid hypothesis, progress in monoclonal antibody technology, and a growing aging population worldwide.

The anti-amyloid antibodies market size is expected to see rapid growth in the next few years. It will grow to $6.54 billion in 2030 at a compound annual growth rate (CAGR) of 14.9%. The growth in the forecast period can be attributed to rising approvals of disease-modifying Alzheimer's therapies, expansion of early diagnostic biomarker screening programs, increasing investments in neuroimmunology research, growing adoption of personalized precision medicine approaches, and advancements in next-generation antibody engineering technologies. Major trends in the forecast period include AI-based biomarker discovery for amyloid-beta aggregation mapping, precision medicine strategies for targeted anti-amyloid antibody therapies, integration of digital health tools for Alzheimer's disease monitoring and progression tracking, cloud-based clinical trial data analytics for neurodegenerative drug development, and advanced biomanufacturing with scalable monoclonal antibody production platforms.

The increasing prevalence of neurodegenerative disorders is anticipated to drive the expansion of the anti-amyloid antibodies market going forward. Neurodegenerative disorders are long-term medical conditions characterized by the gradual degeneration and loss of nerve cells in the brain and nervous system, resulting in progressive cognitive, behavioral, and motor impairments over time. The prevalence of neurodegenerative disorders is rising due to the rapidly aging global population, as older individuals face a significantly higher risk of developing neurological conditions associated with cognitive decline. Anti-amyloid antibodies assist in managing neurodegenerative diseases by helping to reduce the accumulation of amyloid plaques in the brain, enabling earlier therapeutic intervention and slowing disease progression in affected patients. For instance, in March 2024, according to the Alzheimer's Association, a US-based nonprofit health organization, by 2030, the number of Americans aged 65 and above living with Alzheimer's disease is projected to reach 13.8 million by 2060, indicating a significant increase in the prevalence of neurodegenerative disorders over time. Therefore, the rising prevalence of neurodegenerative disorders is driving the growth of the anti-amyloid antibodies market.

Leading companies operating in the anti-amyloid antibodies market are focusing on gaining regulatory approvals for innovative Alzheimer's disease therapies to expand treatment availability, improve patient outcomes, and strengthen their market presence. Regulatory approvals are official authorizations granted by government health agencies confirming that a product meets required safety, efficacy, and quality standards for market use. For example, in July 2024, Eli Lilly and Company, a US-based pharmaceutical company, received approval from the U.S. Food and Drug Administration for Kisunla (donanemab), an anti-amyloid antibody treatment for adults with Alzheimer's disease. The therapy is intended for patients with early symptomatic Alzheimer's disease, including mild cognitive impairment and mild dementia stages. It works by targeting and clearing amyloid plaques in the brain, helping slow cognitive and functional decline.

In December 2024, AbbVie Inc., a US-based provider of neuroscience therapies, biologics, monoclonal antibodies, and pharmaceutical treatments for neurological disorders, acquired Aliada Therapeutics for an undisclosed amount. Through this acquisition, AbbVie intended to reinforce its neuroscience research strengths, expand its Alzheimer's disease pipeline, and advance the development of next-generation anti-amyloid antibody therapies utilizing innovative blood-brain barrier-crossing technology. Aliada Therapeutics is a US-based biotechnology company that offers anti-pyroglutamate amyloid beta (3pE-AB) antibodies for the treatment of Alzheimer's disease and other neurological disorders.

Major companies operating in the anti-amyloid antibodies market are Roche Holding AG, AbbVie Inc., Eli Lilly and Company, Biogen Inc., Eisai Co. Ltd., Prothena Corporation plc, AC Immune SA, Neurimmune AG, SciNeuro Pharmaceuticals, ALZpath Inc., Araclon Biotech S.L., BioArctic AB, Acumen Pharmaceuticals Inc., AstraZeneca plc, Attralus Inc.

North America was the dominant region in the anti-amyloid antibodies market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in anti-amyloid antibodies report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the anti-amyloid antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anti-amyloid antibodies market consists of sales of amyloid-beta-targeting immunotherapies, diagnostic anti-amyloid antibodies, recombinant anti-amyloid antibodies, and investigational Alzheimer's disease antibody therapeutics. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The anti-amyloid antibodies market research report is one of a series of new reports from The Business Research Company that provides anti-amyloid antibodies market statistics, including anti-amyloid antibodies industry global market size, regional shares, competitors with a anti-amyloid antibodies market share, detailed anti-amyloid antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the anti-amyloid antibodies industry. This anti-amyloid antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anti-Amyloid Antibodies Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses anti-amyloid antibodies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anti-amyloid antibodies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The anti-amyloid antibodies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product Type: Monoclonal Antibodies; Polyclonal Antibodies; Other Product Types
• 2) By Target Type: Amyloid Beta Plaques; Soluble Amyloid Beta Oligomers; Protofibrils; Amyloid Precursors
• 3) By Distribution Channel: Direct Sales; Online Pharmacies; Retail Pharmacies; Other Distribution Channels
• 4) By Application: Alzheimer's Disease; Parkinson's Disease; Amyloidosis; Other Application Types
• 5) By End User: Hospitals; Clinics; Research Institutes; Other End Users
• Subsegments:
• 1) By Monoclonal Antibodies: Human Monoclonal Antibodies; Humanized Monoclonal Antibodies; Murine Monoclonal Antibodies; Chimeric Monoclonal Antibodies; Recombinant Monoclonal Antibodies; Bispecific Monoclonal Antibodies
• 2) By Polyclonal Antibodies: Primary Polyclonal Antibodies; Secondary Polyclonal Antibodies; Rabbit Derived Polyclonal Antibodies; Goat Derived Polyclonal Antibodies; Sheep Derived Polyclonal Antibodies
• 3) By Other Product Types: Antibody Fragments; Nanobodies; Antibody Drug Conjugates; Biosimilar Antibodies; Fusion Proteins; Synthetic Antibody Products; Recombinant Protein Based Therapeutics
• Companies Mentioned: Roche Holding AG; AbbVie Inc.; Eli Lilly and Company; Biogen Inc.; Eisai Co. Ltd.; Prothena Corporation plc; AC Immune SA; Neurimmune AG; SciNeuro Pharmaceuticals; ALZpath Inc.; Araclon Biotech S.L.; BioArctic AB; Acumen Pharmaceuticals Inc.; AstraZeneca plc; Attralus Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Anti-Amyloid Antibodies Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Anti-Amyloid Antibodies Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Anti-Amyloid Antibodies Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Anti-Amyloid Antibodies Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Immersive Technologies (AR/VR/XR) & Digital Experiences
  • 4.1.5 Industry 4.0 & Intelligent Manufacturing
• 4.2. Major Trends
  • 4.2.1 AI-Driven Biomarker Discovery For Amyloid-Beta Aggregation Mapping
  • 4.2.2 Precision Medicine Approaches For Targeted Anti-Amyloid Antibody Therapy
  • 4.2.3 Digital Health Integration For Alzheimer's Disease Monitoring And Progression Tracking
  • 4.2.4 Cloud-Based Clinical Trial Data Analysis For Neurodegenerative Disease Drug Development
  • 4.2.5 Advanced Biomanufacturing And Scalable Monoclonal Antibody Production Platforms

5. Anti-Amyloid Antibodies Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Clinics
• 5.3 Research Institutes
• 5.4 Pharmaceutical & Biotechnology Companies
• 5.5 Other End Users

6. Anti-Amyloid Antibodies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Anti-Amyloid Antibodies Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Anti-Amyloid Antibodies PESTEL Analysis (Political, Economical, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Anti-Amyloid Antibodies Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Anti-Amyloid Antibodies Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Anti-Amyloid Antibodies Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Anti-Amyloid Antibodies Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Anti-Amyloid Antibodies Market Segmentation

• 9.1. Global Anti-Amyloid Antibodies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Monoclonal Antibodies, Polyclonal Antibodies, Other Product Types
• 9.2. Global Anti-Amyloid Antibodies Market, Segmentation By Target Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Amyloid Beta Plaques, Soluble Amyloid Beta Oligomers, Protofibrils, Amyloid Precursors
• 9.3. Global Anti-Amyloid Antibodies Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Direct Sales, Online Pharmacies, Retail Pharmacies, Other Distribution Channels
• 9.4. Global Anti-Amyloid Antibodies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Alzheimer's Disease, Parkinson's Disease, Amyloidosis, Other Application Types
• 9.5. Global Anti-Amyloid Antibodies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Clinics, Research Institutes, Other End Users
• 9.6. Global Anti-Amyloid Antibodies Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Human Monoclonal Antibodies, Humanized Monoclonal Antibodies, Murine Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Recombinant Monoclonal Antibodies, Bispecific Monoclonal Antibodies
• 9.7. Global Anti-Amyloid Antibodies Market, Sub-Segmentation Of Polyclonal Antibodies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Primary Polyclonal Antibodies, Secondary Polyclonal Antibodies, Rabbit Derived Polyclonal Antibodies, Goat Derived Polyclonal Antibodies, Sheep Derived Polyclonal Antibodies
• 9.8. Global Anti-Amyloid Antibodies Market, Sub-Segmentation Of Other Product Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Antibody Fragments, Nanobodies, Antibody Drug Conjugates, Biosimilar Antibodies, Fusion Proteins, Synthetic Antibody Products, Recombinant Protein Based Therapeutics

10. Anti-Amyloid Antibodies Market Regional And Country Analysis

• 10.1. Global Anti-Amyloid Antibodies Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Anti-Amyloid Antibodies Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Anti-Amyloid Antibodies Market

• 11.1. Asia-Pacific Anti-Amyloid Antibodies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Anti-Amyloid Antibodies Market, Segmentation By Product Type, Segmentation By Target Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Anti-Amyloid Antibodies Market

• 12.1. China Anti-Amyloid Antibodies Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Anti-Amyloid Antibodies Market, Segmentation By Product Type, Segmentation By Target Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Anti-Amyloid Antibodies Market

• 13.1. India Anti-Amyloid Antibodies Market, Segmentation By Product Type, Segmentation By Target Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Anti-Amyloid Antibodies Market

• 14.1. Japan Anti-Amyloid Antibodies Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Anti-Amyloid Antibodies Market, Segmentation By Product Type, Segmentation By Target Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Anti-Amyloid Antibodies Market

• 15.1. Australia Anti-Amyloid Antibodies Market, Segmentation By Product Type, Segmentation By Target Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Anti-Amyloid Antibodies Market

• 16.1. Indonesia Anti-Amyloid Antibodies Market, Segmentation By Product Type, Segmentation By Target Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Anti-Amyloid Antibodies Market

• 17.1. South Korea Anti-Amyloid Antibodies Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Anti-Amyloid Antibodies Market, Segmentation By Product Type, Segmentation By Target Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Anti-Amyloid Antibodies Market

• 18.1. Taiwan Anti-Amyloid Antibodies Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Anti-Amyloid Antibodies Market, Segmentation By Product Type, Segmentation By Target Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Anti-Amyloid Antibodies Market

• 19.1. South East Asia Anti-Amyloid Antibodies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Anti-Amyloid Antibodies Market, Segmentation By Product Type, Segmentation By Target Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Anti-Amyloid Antibodies Market

• 20.1. Western Europe Anti-Amyloid Antibodies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Anti-Amyloid Antibodies Market, Segmentation By Product Type, Segmentation By Target Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Anti-Amyloid Antibodies Market

• 21.1. UK Anti-Amyloid Antibodies Market, Segmentation By Product Type, Segmentation By Target Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Anti-Amyloid Antibodies Market

• 22.1. Germany Anti-Amyloid Antibodies Market, Segmentation By Product Type, Segmentation By Target Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Anti-Amyloid Antibodies Market

• 23.1. France Anti-Amyloid Antibodies Market, Segmentation By Product Type, Segmentation By Target Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Anti-Amyloid Antibodies Market

• 24.1. Italy Anti-Amyloid Antibodies Market, Segmentation By Product Type, Segmentation By Target Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Anti-Amyloid Antibodies Market

• 25.1. Spain Anti-Amyloid Antibodies Market, Segmentation By Product Type, Segmentation By Target Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Anti-Amyloid Antibodies Market

• 26.1. Eastern Europe Anti-Amyloid Antibodies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Anti-Amyloid Antibodies Market, Segmentation By Product Type, Segmentation By Target Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Anti-Amyloid Antibodies Market

• 27.1. Russia Anti-Amyloid Antibodies Market, Segmentation By Product Type, Segmentation By Target Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Anti-Amyloid Antibodies Market

• 28.1. North America Anti-Amyloid Antibodies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Anti-Amyloid Antibodies Market, Segmentation By Product Type, Segmentation By Target Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Anti-Amyloid Antibodies Market

• 29.1. USA Anti-Amyloid Antibodies Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Anti-Amyloid Antibodies Market, Segmentation By Product Type, Segmentation By Target Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Anti-Amyloid Antibodies Market

• 30.1. Canada Anti-Amyloid Antibodies Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Anti-Amyloid Antibodies Market, Segmentation By Product Type, Segmentation By Target Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Anti-Amyloid Antibodies Market

• 31.1. South America Anti-Amyloid Antibodies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Anti-Amyloid Antibodies Market, Segmentation By Product Type, Segmentation By Target Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Anti-Amyloid Antibodies Market

• 32.1. Brazil Anti-Amyloid Antibodies Market, Segmentation By Product Type, Segmentation By Target Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Anti-Amyloid Antibodies Market

• 33.1. Middle East Anti-Amyloid Antibodies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Anti-Amyloid Antibodies Market, Segmentation By Product Type, Segmentation By Target Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Anti-Amyloid Antibodies Market

• 34.1. Africa Anti-Amyloid Antibodies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Anti-Amyloid Antibodies Market, Segmentation By Product Type, Segmentation By Target Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Anti-Amyloid Antibodies Market Regulatory and Investment Landscape

36. Anti-Amyloid Antibodies Market Competitive Landscape And Company Profiles

• 36.1. Anti-Amyloid Antibodies Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Anti-Amyloid Antibodies Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Anti-Amyloid Antibodies Market Company Profiles
  • 36.3.1. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Eisai Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

37. Anti-Amyloid Antibodies Market Other Major And Innovative Companies

• Prothena Corporation plc, AC Immune SA, Neurimmune AG, SciNeuro Pharmaceuticals, ALZpath Inc., Araclon Biotech S.L., BioArctic AB, Acumen Pharmaceuticals Inc., AstraZeneca plc, Attralus Inc.

38. Global Anti-Amyloid Antibodies Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Anti-Amyloid Antibodies Market

41. Anti-Amyloid Antibodies Market High Potential Countries, Segments and Strategies

• 41.1 Anti-Amyloid Antibodies Market In 2030 - Countries Offering Most New Opportunities
• 41.2 Anti-Amyloid Antibodies Market In 2030 - Segments Offering Most New Opportunities
• 41.3 Anti-Amyloid Antibodies Market In 2030 - Growth Strategies
  • 41.3.1 Market Trend Based Strategies
  • 41.3.2 Competitor Strategies

42. Appendix

• 42.1. Abbreviations
• 42.2. Currencies
• 42.3. Historic And Forecast Inflation Rates
• 42.4. Research Inquiries
• 42.5. The Business Research Company
• 42.6. Copyright And Disclaimer